Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Xencor, inc. symbols : Gsk save search
US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant
Published: 2022-03-25 (Crawled : 21:00) - biospace.com/
GLAXF | $20.2 0.65% -14.18% 510
|
Health Technology
|
| O: 4.57%
H: 0.0%
C: -3.26%
GSK | $40.5 -0.39% -1.09% 2.7M
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
XNCR | $20.11 -1.81% -1.94% 390K
|
Health Technology
|
| O: -0.7%
H: 1.94%
C: -1.47%
VIR | $8.57 -4.46% -4.91% 770K
|
Health Technology
|
| O: -1.07%
H: 0.8%
C: -12.62%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
drug food authorization emergency use authorization
GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19
Published: 2022-01-13 (Crawled : 15:30) - biospace.com/
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
GSK | $40.5 -0.39% -1.09% 2.7M
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: 0.0%
XNCR | $20.11 -1.81% -1.94% 390K
|
Health Technology
|
| O: 0.38%
H: 1.12%
C: -1.31%
VIR | $8.57 -4.46% -4.91% 770K
|
Health Technology
|
| O: 1.05%
H: 1.98%
C: -6.88%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.74%
H: 0.0%
C: 0.0%
covid-19 treatment fda application covid authorization merge emergency use authorization
Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19
Published: 2021-12-17 (Crawled : 13:30) - globenewswire.com
GLAXF | $20.2 0.65% -14.18% 510
|
Health Technology
|
| O: 2.36%
H: 0.46%
C: 0.46%
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: -0.48%
H: 0.0%
C: 0.0%
GSK | $40.5 -0.39% -1.09% 2.7M
|
Health Technology
|
| O: 0.86%
H: 0.0%
C: 0.0%
XNCR | $20.11 -1.81% -1.94% 390K
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
VIR | $8.57 -4.46% -4.91% 770K
|
Health Technology
|
| O: -4.59%
H: 0.0%
C: 0.0%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
covid-19 treatment europe granted covid authorization grant
Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant
Published: 2021-12-07 (Crawled : 09:00) - globenewswire.com
GLAXF | $20.2 0.65% -14.18% 510
|
Health Technology
|
| O: 5.22%
H: 0.0%
C: -1.25%
SNYNF | $92.966 0.07% -2.18% 630
|
Health Technology
|
| O: 3.63%
H: 0.0%
C: 0.0%
GSK | $40.5 -0.39% -1.09% 2.7M
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: 0.0%
XNCR | $20.11 -1.81% -1.94% 390K
|
Health Technology
|
| O: -2.12%
H: 4.74%
C: 2.8%
VIR | $8.57 -4.46% -4.91% 770K
|
Health Technology
|
| O: -6.42%
H: 8.6%
C: 8.45%
SNY | $46.24 0.68% 0.63% 1.6M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
preclinical sars-cov-2 pre-clinical
Gainers vs Losers
| 45% | 55% |
Top 10 Gainers
DYNT | $0.3704 -5.27% 43.09% 5.5M
|
Health Technology
BRTX | $1.32 -1.49% 20.71% 3.3M
|
Professional, Scientific, and T...
PTN | $1.82 -5.21% 15.38% 290K
|
Health Technology
VIAO | $0.308 -26.67% 12.01% 390K
|
Electronic Technology
HNRA | $2.36 -9.58% 11.86% 220K
|
n/a
HYLN 4 | $1.32 -7.04% 8.33% 800K
|
Producer Manufacturing
UMAC | $1.85 -2.12% 8.11% 6.1K
|
BQ | $0.2429 -6.07% 6.63% 99K
|
Consumer Non-Durables
GORO F | $0.534 -0.6% 6.55% 630K
|
Non-Energy Minerals
LBRT 4 | $22.1 -1.6% 6.29% 2.1M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.